Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients.

@article{Yancey2012RiskFF,
  title={Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients.},
  author={Allison Yancey and Michael S. Harris and Akinbode Egbelakin and Jaimie Gilbert and David B. Pisoni and Jamie A Renbarger},
  journal={Pediatric blood & cancer},
  year={2012},
  volume={59 1},
  pages={144-8}
}
BACKGROUND Cisplatin is an effective chemotherapy agent against several pediatric malignancies. One of its side effects is irreversible sensorineural hearing damage that is highly variable with a reported incidence of 22-70%. The aim of this study was to evaluate the incidence and identify clinical predictors of cisplatin-related ototoxicity. PROCEDURES We performed a retrospective chart review of 102 pediatric patients who had completed cisplatin therapy for osteosarcoma, neuroblastoma… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 18 references

Practical grading system for evaluating cisplatin ototoxicity in children.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2010
View 4 Excerpts
Highly Influenced

Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2005
View 4 Excerpts
Highly Influenced

Critical need for international consensus on ototoxicity assessment criteria.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2010
View 1 Excerpt

Similar Papers

Loading similar papers…